全文获取类型
收费全文 | 425370篇 |
免费 | 30097篇 |
国内免费 | 6251篇 |
专业分类
耳鼻咽喉 | 5654篇 |
儿科学 | 8607篇 |
妇产科学 | 10527篇 |
基础医学 | 57551篇 |
口腔科学 | 12478篇 |
临床医学 | 36125篇 |
内科学 | 84201篇 |
皮肤病学 | 8881篇 |
神经病学 | 29401篇 |
特种医学 | 15876篇 |
外国民族医学 | 103篇 |
外科学 | 65801篇 |
综合类 | 20150篇 |
一般理论 | 70篇 |
预防医学 | 20939篇 |
眼科学 | 10826篇 |
药学 | 36408篇 |
54篇 | |
中国医学 | 5715篇 |
肿瘤学 | 32351篇 |
出版年
2021年 | 4814篇 |
2020年 | 4010篇 |
2019年 | 4364篇 |
2018年 | 6188篇 |
2017年 | 5123篇 |
2016年 | 4983篇 |
2015年 | 6470篇 |
2014年 | 8837篇 |
2013年 | 10374篇 |
2012年 | 14592篇 |
2011年 | 14900篇 |
2010年 | 9574篇 |
2009年 | 8549篇 |
2008年 | 12378篇 |
2007年 | 13135篇 |
2006年 | 12813篇 |
2005年 | 11628篇 |
2004年 | 10264篇 |
2003年 | 9819篇 |
2002年 | 9232篇 |
2001年 | 29015篇 |
2000年 | 29423篇 |
1999年 | 24296篇 |
1998年 | 5426篇 |
1997年 | 4513篇 |
1996年 | 4027篇 |
1995年 | 3764篇 |
1994年 | 3363篇 |
1993年 | 2991篇 |
1992年 | 16186篇 |
1991年 | 14932篇 |
1990年 | 14279篇 |
1989年 | 14049篇 |
1988年 | 12668篇 |
1987年 | 12131篇 |
1986年 | 11165篇 |
1985年 | 10372篇 |
1984年 | 6944篇 |
1983年 | 5622篇 |
1982年 | 2729篇 |
1979年 | 5486篇 |
1978年 | 3359篇 |
1977年 | 2967篇 |
1975年 | 2642篇 |
1974年 | 3069篇 |
1973年 | 2866篇 |
1972年 | 2833篇 |
1971年 | 2773篇 |
1970年 | 2515篇 |
1969年 | 2550篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Post-induction hypotension is common and associated with postoperative complications. We hypothesised that pneumatic leg compression reduces post-induction hypotension in elderly patients undergoing robot-assisted laparoscopic prostatectomy. In this double-blind randomised study, patients were allocated randomly to the pneumatic leg compression group (n = 50) or control (n = 50). In the intervention group, pneumatic leg compression was initiated before induction of anaesthesia. In the control group, pneumatic leg compression was initiated 20 min after anaesthesia induction. The primary outcome was the incidence of post-induction hypotension in these groups. Post-induction hypotension was defined as systolic blood pressure < 90 mmHg during the first 20 min after induction. Haemodynamic variables and area under the curve of post-induction systolic blood pressure over time were assessed. Complications associated with pneumatic leg compression were recorded, including: peripheral neuropathy; compartment syndrome; extensive bullae beneath the leg sleeves; and pulmonary thromboembolism. The incidence of post-induction hypotension decreased in the pneumatic leg compression group compared with that in the control group; 5 (10%) vs. 29 (58%), respectively, p < 0.001. In the pneumatic leg compression group, the lowest systolic, diastolic and mean blood pressures 20 min after induction of anaesthesia were significantly greater than the control group. Pneumatic leg compression resulted in an increased area under the curve of systolic blood pressure in the first 20 min after induction, p = 0.001. There were no pneumatic leg compression-related complications. Pneumatic leg compression reduced post-induction hypotension in elderly patients undergoing robot-assisted laparoscopic prostatectomy, suggesting that it is an effective and safe intervention to prevent post-induction hypotension among elderly patients undergoing general anaesthesia. 相似文献
2.
Biaoming Xu Yu Chen Mingjing Peng Jin Hai Zheng Chaohui Zuo 《International journal of cancer. Journal international du cancer》2023,152(2):110-122
Pancreatic cancer (PC) is a cancer of the digestive system, and pancreatic ductal adenocarcinoma (PDAC) accounts for approximately 90% of all PC cases. Exosomes derived from PDAC (PDAC-exosomes) promote PDAC development and metastasis. Exosomes are nanoscale vesicles secreted by most cells, which can carry biologically active molecules and mediate communication and cargo transportation among cells. Recent studies have focused on transforming exosomes into good drug delivery systems (DDSs) to improve the clinical treatment of PDAC. This review considers PDAC as the main research object to introduce the role of PDAC-exosomes in PDAC development and metastasis. This review focuses on the following two themes: (a) the great potential of PDAC-exosomes as new diagnostic markers for PDAC, and (b) the transformation of exosomes into potential DDSs. 相似文献
3.
Buket Bakan Fatih Oltulu Yeliz Y?ld?r?m Altu? Yava?o?lu Sinan Akg?l Nefise ülkü Karabay Yava?o?lu 《Arhiv za higijenu rada i toksikologiju》2023,74(3):207
The aim of this safety study in mice was to determine in vivo toxicity and biodistribution potential of a single and multiple doses of L-glutamic acid-g-p(HEMA) polymeric nanoparticles as a drug delivery system. The single dose did not cause any lethal effect, and its acute oral LD50 was >2.000 mg/kg body weight (bw). Multiple doses (25, 50, or 100 mg/kg bw) given over 28 days resulted in no significant differences in body and relative organ weights compared to control. These results are supported by biochemical and histological findings. Moreover, nanoparticle exposure did not result in statistically significant differences in micronucleus counts in bone marrow cells compared to control. Nanoparticle distribution was time-dependent, and they reached the organs and even bone marrow by hour 6, as established by ex vivo imaging with the IVIS® spectrum imaging system. In conclusion, L-glutamic acid-g-p(HEMA) polymeric nanoparticles appear biocompatible and have a potential use as a drug delivery system.KEY WORDS: biocompatibility, blood biochemistry, genotoxicity, histology, in vivo toxicity, micronucleus test, polymers 相似文献
4.
目的观察分析眼球钝挫伤合并外伤性晶状体脱位患者周边隐匿性视网膜病变的临床特点及预后。 方法本研究纳入2013年1月至2020年1月在柳州市人民医院眼科住院诊断为眼球钝挫伤合并外伤性晶状体脱位,并行23G微创玻璃体切割联合白内障摘除手术的72例(72眼)患者。根据裂隙灯和超声生物显微镜(UBM)检查,将患者分为晶状体不全脱位组和全脱位组,详细记录2组患者的术中周边视网膜病变情况,并分析其临床特征及疗效。 结果眼球钝挫伤合并外伤性晶状体脱位患者中有周边隐匿性视网膜病变的占72.22%,其中晶状体不全脱位组发生率高达80.95%,显著大于晶状体全脱位组的60.00%(P<0.05)。2组患者的周边隐匿性视网膜病变均以隐匿性视网膜裂孔、变性和出血为最常见。所有患者术后视网膜情况稳定,视力预后较好。 结论眼球钝挫伤合并外伤性晶状体脱位患者常出现周边隐匿性视网膜病变,最常见的是视网膜裂孔、出血、变性。23G微创玻璃体切割联合白内障摘除手术是有效治疗手段,具有创伤小、并发症少的优势。 相似文献
5.
【目的】 通过比较2019年获得“中国科技期刊卓越行动计划”领军期刊项目资助的期刊(以下简称“领军期刊”)与其对标期刊,探索我国科技期刊缩小与世界顶级期刊差距的对策,为我国一流科技期刊建设提供参考和借鉴。【方法】 利用Web of Science (WoS) 数据库和期刊官网,检索并总结领军期刊与其对标期刊的各项指标数据,分析领军期刊最近5年来的发展情况。【结果】 22种领军期刊的主要指标数据明显上升。2020年领军期刊共发表Article 和Review文章4025篇,比2019年的2630篇增长53.0%,2020年刊均载文量为183篇,比2019年的120篇增长53.0%;领军期刊总被引频次由2019年的99767 次大幅增长至2020年的153610次,增幅达54.0%;2020年领军期刊的平均被引半衰期为3.73年,而对标期刊的平均被引半衰期为9.35年。2020年,16种领军期刊跻身JCR学科排名前10%,10种领军期刊跻身JCR学科排名前5%。【结论】 领军期刊应构建良性的期刊发展生态、动态调整期刊的发展目标、紧扣国家战略和重大需求布局期刊发展方向、重视人才发展与储备、构建自主可控的国际传播平台与渠道,以完成引领行业发展的使命任务,实现可持续发展,从而带动我国期刊行业的整体发展与进步。 相似文献
6.
卫逸涛肖惠敏谢银环孙丽军 《中华健康管理学杂志》2022,(8):547-552
目的了解老年人生命晚期获知疾病相关信息意向及影响因素。方法2016年10月至2017年6月,采用生命晚期疾病信息意向问卷,利用方便抽样法对福州市中心城区7所养老机构及15个社区的414例年龄≥60岁的老年人进行横断面调查,采用单因素分析、多元线性回归与有序多分类logistic回归分析老年人对疾病相关信息的需求水平、获知程度意向及其影响因素。结果414例老年人疾病相关信息需求得分为(17.1±4.9)分;48.8%(202/414)希望详尽知晓,30.7%(127/414)希望选择性了解,20.5%(85/414)不想知道任何信息;多元线性回归分析显示,年龄、文化程度、是否接受/见过其他生命维持治疗(LSTs)是影响老年人疾病相关信息需求水平的主要因素(标准化回归系数分别为-0.141、0.116、0.115,均P<0.05);有序多分类logistic分析显示,年龄(以60~69岁为参照,70~79岁:OR=0.544,95%CI:0.310~0.957;80~89岁:OR=0.526,95%CI:0.289~0.956)、文化程度(以小学及以下为参照,大专及以上:OR=2.166,95%CI:1.093~4.290)、主要生活费来源(以其他补贴为参照,家人支持:OR=7.303,95%CI:1.157~46.108;退休金:OR=9.288,95%CI:1.502~57.415;公积金/储蓄:OR=15.676,95%CI:2.122~115.793)、是否接受/见过其他LSTs(以是为参照,OR=1.985,95%CI:1.150~3.425)是影响老年人疾病相关信息获知程度意向的主要因素。结论老年人生命晚期获知疾病相关信息的意向程度较高,年龄、文化程度、主要生活费来源、是否接受/见过其他生命维持治疗等是其主要影响因素。 相似文献
7.
Clinical and Experimental Medicine - Recently, the use of novel targeted drugs significantly improved the overall response rate (ORR) and survival of patients with relapsed/refractory chronic... 相似文献
8.
9.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
10.